Market Access & Real-World Evidence
Navigating Healthcare Complexities with Strategic Insight
We provide end-to-end market access support — combining data-driven research, expert consulting, and regional insight — to help your products reach the right patients effectively across complex healthcare markets and regulatory environments.
What the program covers
Market Access Strategy & Consulting
Strategic guidance to navigate complex healthcare markets, develop compelling value propositions, and optimize product positioning.
Pricing, Reimbursement & Health Economics
Expert support in pricing strategy, reimbursement dossier preparation, and health economic modeling to secure sustainable access.
Real-World Evidence (RWE) & Data Analytics
Comprehensive real-world evidence generation through advanced data analytics and observational studies.
Comprehensive Market Research
In-depth market intelligence through both quantitative and qualitative methodologies — powered by a dedicated call center and advanced analytical capabilities that deliver contextually relevant data.
Navigate Africa's Healthcare Landscape
A multidisciplinary team delivers tailored strategies that empower you to make informed, evidence-based decisions, rooted in deep expertise of African healthcare markets.
Frequently asked questions
- What does market access mean in pharma?
- Market access is the work of getting an approved therapy reimbursed, priced, and available to the patients who need it. It covers pricing strategy, reimbursement dossiers, health economics, and the evidence that payers and regulators require.
- What is Real World Evidence (RWE)?
- Real World Evidence is clinical evidence generated from routine care rather than from a controlled trial — patient registries, prescription data, and outcomes observed in normal practice. Gaya Pharma runs RWE studies across Africa to show how therapies perform in local healthcare settings.
- Why is Real World Evidence important in African markets?
- Trial data is usually generated outside Africa, so payers and regulators lack local outcome evidence. RWE fills that gap by measuring effectiveness, safety, and treatment patterns in African patients, which supports health technology assessment and reimbursement decisions.
- Does Gaya Pharma support pricing and reimbursement submissions?
- Yes. Gaya Pharma provides pricing and reimbursement strategy, health economics analysis, and the supporting data and market research needed for submissions in complex African healthcare markets.